How Diabetes Medications SGLT2 Inhibitors and GLP-1 RAs Protect Kidneys and Hearts in CKD
SGLT2 inhibitors and GLP-1 receptor agonists provide significant kidney and cardiovascular protection in chronic kidney disease patients beyond their blood sugar-lowering effects.
Quick Facts
What This Study Found
SGLT2 inhibitors protect kidneys by restoring tubuloglomerular feedback and reducing renal injury, while GLP-1 RAs reduce oxidative stress and inflammation — both offering organ protection beyond glycemic control.
Key Numbers
Reviews multiple landmark trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY, FLOW); summarizes mechanisms and outcomes.
How They Did This
Narrative review summarizing clinical trials and mechanistic studies evaluating SGLT2i and GLP-1 RA effects on kidney function, cardiovascular outcomes, and disease progression in CKD/DKD.
Why This Research Matters
Demonstrates that these diabetes drugs should be considered essential kidney and heart medications, not just blood sugar treatments, for CKD patients.
The Bigger Picture
The repurposing of diabetes medications as kidney and heart protectors represents one of the most important therapeutic advances in nephrology, potentially changing how CKD is managed regardless of diabetes status.
What This Study Doesn't Tell Us
Narrative review format lacks the systematic rigor of meta-analysis; long-term outcomes data still accumulating for some populations; not all CKD stages equally studied.
Questions This Raises
- ?Can combining SGLT2 inhibitors with GLP-1 RAs provide additive organ protection in CKD?
- ?At what CKD stage should these medications be initiated for maximum benefit?
Trust & Context
- Key Stat:
- Beyond glucose SGLT2i and GLP-1 RAs protect kidneys and hearts through mechanisms independent of blood sugar control
- Evidence Grade:
- Narrative review synthesizing clinical trial and mechanistic evidence; individual trials provide strong evidence but review format is less rigorous than systematic review.
- Study Age:
- Published in 2025, incorporating the latest clinical trial data on kidney and cardiovascular protection.
- Original Title:
- Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 18(8) (2025)
- Authors:
- Rabbani, Syed Arman(2), El-Tanani, Mohamed(4), Kumar, Rakesh, Saini, Manita, El-Tanani, Yahia, Sharma, Shrestha, Aljabali, Alaa A A, Hajeer, Eman, Rizzo, Manfredi
- Database ID:
- RPEP-13159
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can diabetes drugs protect kidneys even without diabetes?
Yes — SGLT2 inhibitors in particular have shown kidney-protective effects in CKD patients regardless of diabetes status, through mechanisms like restoring kidney filtration balance and reducing inflammation.
How do GLP-1 medications protect the kidneys?
GLP-1 receptor agonists reduce oxidative stress and inflammation in kidney tissue, slow disease progression, and provide additional cardiovascular benefits — all independent of their blood sugar-lowering effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13159APA
Rabbani, Syed Arman; El-Tanani, Mohamed; Kumar, Rakesh; Saini, Manita; El-Tanani, Yahia; Sharma, Shrestha; Aljabali, Alaa A A; Hajeer, Eman; Rizzo, Manfredi. (2025). Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.. Pharmaceuticals (Basel, Switzerland), 18(8). https://doi.org/10.3390/ph18081130
MLA
Rabbani, Syed Arman, et al. "Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.." Pharmaceuticals (Basel, 2025. https://doi.org/10.3390/ph18081130
RethinkPeptides
RethinkPeptides Research Database. "Repurposing Diabetes Therapies in CKD: Mechanistic Insights,..." RPEP-13159. Retrieved from https://rethinkpeptides.com/research/rabbani-2025-repurposing-diabetes-therapies-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.